Left Atrial Structural and Functional Response in Kidney Transplant Recipients Treated With Mesenchymal Stromal Cell Therapy and Early Tacrolimus Withdrawal

被引:8
|
作者
Meucci, Maria Chiara [1 ,4 ]
Reinders, Marlies E. J. [2 ,5 ]
Groeneweg, Koen E. [2 ]
Bezstarosti, Suzanne [2 ,3 ]
Marsan, Nina Ajmone [1 ]
Bax, Jeroen J. [1 ,6 ]
De Fijter, Johan W. [2 ]
Delgado, Victoria [1 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Cardiol, Albinusdreef 2, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands
[4] Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc Med, Rome, Italy
[5] Erasmus MC, Erasmus Univ Med Ctr, Transplant Inst, Dept Internal Med, Rotterdam, Netherlands
[6] Univ Turku, Turku Univ Hosp, Heart Ctr, Turku, Finland
[7] Hosp Badalona Germans Trias & Pujol, Fundacio Inst Invest Ciencies Salut Germans Trias, Badalona, Spain
关键词
Left atrium; Atrial function; Kidney transplantation; Mesenchymal stem cells; Immunosuppression; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; DISEASE; ECHOCARDIOGRAPHY; RECOMMENDATIONS; OUTCOMES; UPDATE; VOLUME;
D O I
10.1016/j.echo.2022.10.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Autologous bone marrow-derived mesenchymal stromal cell (MSC) therapy and withdrawal of calcineurin inhibitors (CNIs) has been shown to improve systemic blood pressure control and left ventricular hypertrophy regression in kidney transplant recipients. In the current subanalysis, we aimed to evaluate the impact of this novel immunosuppressive regimen on the longitudinal changes of left atrial (LA) structure and function after kidney transplantation.Methods: Kidney transplant recipients randomized to MSC therapy-infused at weeks 6 and 7 after transplan-tation, with complete discontinuation at week 8 of tacrolimus (MSC group)-or standard tacrolimus dose (con-trol group) were evaluated with transthoracic echocardiography at weeks 4 and 24 after kidney transplantation. The changes in echocardiographic parameters were compared between the randomization arms using an analysis of covariance model adjusted for baseline variable.Results: Fifty-four participants (MSC therapy = 27; tacrolimus therapy = 27) were included. There was no signif-icant interaction between the allocated treatment and the changes of indexed maximal LA volume (LAVImax) over the study period. Conversely, between 4 and 24 weeks post-transplantation, an increase in indexed minimal LA volume (LAVImin) was observed in control subjects, while it remained unchanged in the MSC group, leading to a significant difference between groups (P = .021). Additionally, patients treated with MSC therapy showed a benefit in LA function, assessed by a significant interaction between changes in LA emptying fraction and LA reservoir strain and the randomization arm (P = .012 and P = .027, respectively).Conclusions: The combination of MSC therapy and CNIs withdrawal prevents progressive LA dilation and dysfunction in the first 6 months after kidney transplantation. LAVImin and LA reservoir strain may be more sen-sitive markers of LA reverse remodeling, compared with LAVImax. (J Am Soc Echocardiogr 2023;36:172-9.)
引用
收藏
页码:172 / 179
页数:8
相关论文
共 50 条
  • [21] Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy
    Gillard, Pieter
    Rustandi, Maria
    Efendi, Achmad
    Lee, Da Hae
    Ling, Zhidong
    Hilbrands, Robert
    Kuypers, Dirk
    Mathieu, Chantal
    Jacobs-Tulleneers-Thevissen, Daniel
    Gorus, Frans
    Pipeleers, Daniel
    Keymeulen, Bart
    TRANSPLANTATION, 2014, 98 (04) : 451 - 457
  • [22] AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients
    Kim, Helena
    Ali, Rafia
    Short, Samuel
    Kaunfer, Sarah
    Krishnamurthy, Shobana
    Durai, Lavanya
    Yilmam, Osman
    Shenoy, Tushar
    Monson, Audrey E.
    Thomas, Charlotte
    Park, Isabel
    Martini, Dylan
    Newcomb, Richard
    Shapiro, Roman M.
    Soiffer, Robert J.
    DeFilipp, Zachariah
    Baron, Rebecca M.
    Gupta, Shruti
    Sise, Meghan E.
    Leaf, David E.
    BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 178 - 188
  • [23] AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients
    Helena Kim
    Rafia Ali
    Samuel Short
    Sarah Kaunfer
    Shobana Krishnamurthy
    Lavanya Durai
    Osman Yilmam
    Tushar Shenoy
    Audrey E. Monson
    Charlotte Thomas
    Isabel Park
    Dylan Martini
    Richard Newcomb
    Roman M. Shapiro
    Robert J. Soiffer
    Zachariah DeFilipp
    Rebecca M. Baron
    Shruti Gupta
    Meghan E. Sise
    David E. Leaf
    Bone Marrow Transplantation, 2024, 59 : 178 - 188
  • [24] Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac).
    Budde, K.
    Bunnapradist, S.
    Patel, S. J.
    Stevens, D. R.
    Meier-Kriesche, U.
    Suwelack, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 689 - 689
  • [25] Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study
    Reinders, Marlies E. J.
    Groeneweg, Koen E.
    Hendriks, Sanne H.
    Bank, Jonna R.
    Dreyer, Geertje J.
    de Vries, Aiko P. J.
    van Pel, Melissa
    Roelofs, Helene
    Huurman, Volkert A. L.
    Meij, Paula
    Moes, Dirk J. A. R.
    Fibbe, Willem E.
    Claas, Frans H. J.
    Roelen, Dave L.
    van Kooten, Cees
    Kers, Jesper
    Heidt, Sebastiaan
    Rabelink, Ton J.
    de Fijter, Johan W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (09) : 3055 - 3065
  • [26] Comparison of Reduced-Dose and Labeled-Dose Belatacept Conversion with Immediate or Early Tacrolimus Withdrawal in Kidney Transplant Recipients without Maintenance Corticosteroids
    Kuzaro, H.
    Shields, A. R.
    Cuffy, M.
    Woodle, E. S.
    Pembaur, K.
    Safdar, S.
    Huang, S.
    Krisko, G.
    Raabe, S.
    Parks, R.
    Kremer, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 918 - 919
  • [27] PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EC-MPS IN KIDNEY TRANSPLANT RECIPIENTS (KTR) CO-TREATED WITH TACROLIMUS IN THE EARLY POSTOPERATIVE PHASE
    Stracke, Sylvia
    Shipkova, Maria
    Mayer, Jens
    Keller, Frieder
    John, Jessica
    Wittau, Mathias
    Henne-Bruns, Doris
    Wieland, Eberhard
    TRANSPLANT INTERNATIONAL, 2013, 26 : 91 - 91
  • [28] EARLY EVALUATION OF GENETICALLY ENGINEERED MESENCHYMAL STROMAL STEM CELL THERAPY FOR PREVENTION OF LEFT VENTRICULAR DYSFUNCTION IN PIGS
    Malik, N.
    Wallrapp, C.
    Geigle, P.
    Lewis, A. L.
    Stratford, P. W.
    Holt, C. M.
    HEART, 2009, 95 : A65 - A66
  • [29] Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal
    Toenshoff, Burkhard
    Tedesco-Silva, Helio
    Ettenger, Robert
    Christian, Martin
    Bjerre, Anna
    Dello Strologo, Luca
    Marks, Stephen D.
    Pape, Lars
    Veldandi, Udaykiran
    Lopez, Patricia
    Cousin, Marc
    Pandey, Priti
    Meier, Matthias
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (01) : 123 - 137
  • [30] Prevalence of hypertension using ambulatory blood pressure monitoring in paediatric kidney transplant recipients treated with early steroid withdrawal immunosuppressive regimes.
    Dowsett, Thomas
    Shenoy, Mohan
    PEDIATRIC NEPHROLOGY, 2023, 38 (07) : 2329 - 2329